Evidence map›Paper›PMID 25523926›Full record

ArticleJournal of immunological methods2015

In vivo elimination of parental clones in general and site-directed mutagenesis.

Erika G Holland, Felicity E Acca, Kristina M Belanger, Mary E Bylo, Brian K Kay, Michael P Weiner, Margaret M Kiss

Abstract read
In one paragraph

Article in Journal of immunological methods, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Erika G HollandAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
Felicity E AccaAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
Kristina M BelangerAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
Mary E ByloAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
Brian K KayUniversity of Illinois at Chicago, 845 West Taylor Street, Chicago, IL 60607, United States.
Michael P WeinerAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States.
Margaret M KissAxioMx, Inc., 688 E. Main St., Branford, CT 06405, United States. Electronic address: mkiss@axiomxinc.com.

Funding

Technology Development for Recombinant Affinity ReagentsU54DK093444 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KAY, BRIAN KENNETH · 2011 to 2013
$3.6M
NIDDK NIH HHS 1 U54 DK093444-01NIDDK NIH HHS U54 DK093444
6 · The paper itself

Abstract

The Eco29k I restriction endonuclease is a Sac II isoschizomer that recognizes the sequence 5'-CCGCGG-3' and is encoded, along with the Eco29k I methylase, in the Escherichia coli strain 29k. We have expressed the Eco29k I restriction-methylation system (RM2) in E. coli strain TG1 to produce the strain AXE688. We have developed a directed molecular evolution (DME) mutagenesis method that uses Eco29k I to restrict incoming parental DNA in transformed cells. Using our DME method, we have demonstrated that our AXE688 strain results in mutated directed molecular evolution libraries with diversity greater than 10(7) from a single transformation and with greater than 90% recombinant clones.

Indexed as

Cloning, MolecularDeoxyribonucleases, Type II Site-SpecificDirected Molecular EvolutionDNA Modification MethylasesDNA, RecombinantEscherichia coliGene LibraryGenetic VariationGenetic VectorsMutagenesis, Site-DirectedCCGCGG-specific type II deoxyribonucleasesDeoxyribonucleases, Type II Site-SpecificDNA Modification MethylasesDNA, RecombinantAffinity maturationDirected evolutionPhage displaySite-directed mutagenesis

Identifiers

PMID25523926
PMCPMC4394739

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.